I-MED Pharma innovates and distributes medical, surgical and veterinary eye care products. Our mission is simple yet challenging: perfecting sight. To achieve this we continually conduct research, develop and source the most effective and advanced solutions to eye disorders like cataracts, corneal transplants, dry eye, and glaucoma.

Established over twenty years ago, I-MED remains uniquely focused on ophthalmology and is divided into three functional business units: Animal Health, Pharma and Surgical. Our focus on improving vision and our experience in the field is supported by our commitment to:

1. Quality - a commitment to achieve world class quality in everything we do and sell
2. Customer Service - exceed expectations with every order and shipment
3. Innovation - provide proven cutting-edge products to help eye care professionals obtain superior results
4. Technical Expertise - recruiting and developing qualified and skilled staff with decades of ophthalmic industry know-how
5. Value - provide unmatched value by offering quality products at competitive prices

The SOLX® Gold Shunt is the next generation treatment platform that has the potential to change the current approach to glaucoma therapy. It provides a less invasive, yet highly effective glaucoma treatment for reducing Intraocular Pressure (IOP) associated with glaucoma in patients without creating a bleb.

The SOLX® Gold Shunt is the first biocompatible, 24-karat gold implant that uses the eye's natural pressure differential (uveal scleral outflow) to reduce intraocular pressure (IOP) without a bleb. It is approximately 3 mm wide, 6 mm long; it is about the thickness of a human hair. The Gold Shunt's thin structure is designed for implantation through a single micro-incision. It contains numerous micro-channels that bridge the anterior chamber and the suprachoroidal space, controlling aqueous outflow to reduce IOP. The shunt is virtually undetectable by the patient and is intended to last indefinitely.

The current SOLX® Gold Shunt GMS Plus model has the same outside dimensions are the same as the original Gold Shunt, however, the internal architecture incorporates a greater outflow facility (i.e., lower flow resistance) that provides lower intra-ocular pressure (IOP) with minimal glaucoma medications.

Online PR News – 09-July-2010 – I-MED Surgical, a division of I-MED Pharma, announced today that Health Canada has granted approval of the Rayner C-flex® and Superflex® aspheric intraocular lenses for visual correction following cataract surgery. As the exclusive Canadian distributor, I-MED Surgical will begin a phased commercial launch of these new lenses with full distribution expected by Q4 2010.

Rayner C-flex Aspheric and Superflex® Aspheric IOLs are spherically aberration-neutral with the aspheric modification being applied to the anterior surface of the IOL, providing uniform refractive power from the centre of the optic to its edge, for optimal visual outcomes. The depth of field of this lens is very similar to standard IOLs whilst having the advantages discussed above. In addition, the Rayner C-flex Aspheric and Superflex® Aspheric IOLs offer the technology of the existing IOL platform. These include the Amon-Apple Enhanced Square Edge for exemplary low posterior capsular opacification rates, AVH (anti-vaulting haptic) Technology for optimal centration, and a single use Soft-tipped injector capable of IOL insertion through a sub 3mm incision.

The Rayner C-flex (970C) Aspheric and Superflex® (920H) Aspheric
• Increased contrast sensitivity
• Increased functional visual acuity
• Optimised visual outcomes even under reduced lighting conditions
• Increased depth of field compared with designs corrected for corneal spherical aberration, such as negative aberration designs
• Less susceptible to the effects of tilt and decentration compared with negative aberration designs – a benefit which is further enhanced by the incorporation of AVH Technology®.

“The addition of the Rayner aberration-neutral optic technology intraocular lens (IOL) selection to our offering allows I-MED Surgical to provide our clients a complete and totally innovative IOL line which permits the surgeon to offer their patients the most modern and effective corrective implantable lenses following cataract surgery,” said Dr. Ilan Hofmann, President, I-MED Pharma. “The design, IOL material, optics and delivery system is unmatched in quality and performance by any other supplier currently on the market. I-MED Surgical, a company with more than two decades of experience in the ophthalmic surgical market, is pleased to offer Canadian ophthalmologists the best selection of intraocular lenses manufactured by Rayner, the company that invented intraocular lenses.”